Browsing by Author "Medine E.İ."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Investigation of therapeutic efficiency of phenytoin (PHT) labeled with radioactive 131I in the cancer cell lines
    (Springer Netherlands, 2016) Uzaras C.; Avcıbaşı U.; Demiroğlu H.; Medine E.İ.; Kılçar A.Y.; Müftüler F.Z.B.; Ünak P.
    The aim of this study is to determine the incorporations of PHT radiolabeled with 131I (131I-PHT) on U-87 MG, Daoy and A549 cancerous cell lines. For this, cold and radio-labeling studies were carried out. The radio-labeling yield of 131I-PHT was obtained about 95 %. Subsequently, cell culture studies were carried out and radio-labeling yields of 131I, 131I-PHT on U-87 MG, Daoy and A549 cancerous cells were investigated. Cell culture studies demonstrated that the incorporation values of 131I-PHT on the three cell lines decreased with increasing radioactivity. Consequently, 131I-PHT may be a good radiopharmaceutical for targeting radionuclide therapy of Central Nervous System Tumors. © 2015, Akadémiai Kiadó, Budapest, Hungary.
  • No Thumbnail Available
    Item
    99mTc(I) carbonyl-radiolabeled lipid based drug carriers for temozolomide delivery and bioevaluation by in vitro and in vivo
    (Walter de Gruyter GmbH, 2019) Arı K.; Uçar E.; İçhedef Ç.; Kılçar A.Y.; Medine E.İ.; Parlak Y.; Bilgin B.E.S.; Aydın B.; Gümüşer F.G.; Teksöz S.
    In preclinical research radiolabeled nanoparticles have been attracting interest as a new class of imaging probes. Assuming good stability of solid lipid nanoparticles (SLNs) under physiological conditions, radiolabeled SLNs can be used for imaging and measuring uptake in target tissue. Present study was performed to evaluate biological behavior of temozolomide (TMZ) loaded solid lipid nanoparticles (SLN-TMZ) in vivo and in vitro. Lipid nanoparticles were prepared by emulsification and low-temperature solidification method. ζ potential, morphology and particle size of nanoparticles were determined. Biological behavior of 99mTc(CO)3+ radiolabeled SLN-TMZ were investigated in vitro on U87/Daoy cell lines and in vivo on female Wistar Albino rats. Obtained results of in vitro incorporation, in vivo biodistribution and gamma imaging studies on radiolabeled SLN-TMZ show that the radiolabeled solid lipid nanoparticles could have potential as a drug delivery system for TMZ. © 2019 Walter de Gruyter GmbH. All rights reserved.
  • No Thumbnail Available
    Item
    Thymoquinone glucuronide conjugated magnetic nanoparticle for bimo-dal imaging and treatment of cancer as a novel theranostic platform
    (Bentham Science Publishers, 2021) İnce İ.; Müftüler Z.B.; Medine E.İ.; Güldü Ö.K.; Takan G.; Ergönül A.; Parlak Y.; Yıldırım Y.; Çakar B.; Bilgin E.S.; Aras Ö.; Göker E.; Ünak P.
    Background: Theranostic oncology combines therapy and diagnosis and is a new field of medicine that specifically targets the disease by using targeted molecules to destroy the cancer-ous cells without damaging the surrounding healthy tissues. Objective: We aimed to develop a tool that exploits enzymatic TQ release from glucuronide (G) for the imaging and treatment of lung cancer. We added magnetic nanoparticles (MNP) to enable magnetic hyperthermia and MRI, as well as 131I to enable SPECT imaging and radionuclide thera-py. Methods: A glucuronide derivative of thymoquinone (TQG) was enzymatically synthesized and conjugated with the synthesized MNP and then radioiodinated with 131I. New Zealand white rab-bits were used in SPECT and MRI studies, while tumor modeling studies were performed on 6–7-week-old nude mice utilized with bioluminescence imaging. Results: Fourier-transform infrared spectroscopy (FTIR) and nuclear magnetic resonance (NMR) spectra confirmed the expected structures of TQG. The dimensions of nanoparticles were below 10 nm and they had rather polyhedral shapes. Nanoparticles were radioiodinated with 131I with over 95% yield. In imaging studies, in xenograft models, tumor volume was significantly reduced in TQGMNP-treated mice but not in non-treated mice. Among mice treated intravenously with TQGMNP, xenograft tumor models disappeared after 10 and 15 days, respectively. Conclusion: Our findings suggest that TQGMNP in solid, semi-solid and liquid formulations can be developed using different radiolabeling nuclides for applications in multimodality imaging (SPECT and MRI). By altering the characteristics of radionuclides, TQGMNP may ultimately be used not only for diagnosis but also for the treatment of various cancers as an in vitro diagnostic kit for the diagnosis of beta glucuronidase-rich cancers. © 2021 Bentham Science Publishers.